Top

Osteoporosis International

Published in:

Open Access 01-11-2009 | Original Article

Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT

Authors: J. E. M. Brouwers, B. van Rietbergen, R. Huiskes, K. Ito

Published in: Osteoporosis International | Issue 11/2009

Abstract

Summary

Using in vivo microcomputed tomography (micro-CT), we found in parathyroid hormone (PTH)-treated osteopenic rats linear increases in cortical and trabecular, due to increased trabecular thickness and number, bone mass. Bone was formed in cavities, leading to restoral of nearly cleaved trabeculae. For the first time, effects in PTH-treated rats were analyzed longitudinally.

Introduction

Our aims were to over time (1) determine changes in trabecular thickness and number after PTH, (2) compare responses to PTH between the meta- and epiphysis, (3) determine effects of PTH on mineralization and mechanical properties, (4) determine locations of new bone formation due to PTH on a microlevel, and (5) determine the predictive value of bone structural properties for gain in bone mass after PTH.

Methods

Adult rats were divided into ovariectomy (OVX; n = 8), SHAM-OVX (n = 8), and OVX and PTH treatment (n = 9). Between weeks 8 and 14, PTH rats received daily subcutaneous PTH injections (60 μg/kg/day). At weeks 0, 8, 10, 12, and 14, in vivo micro-CT scans were made of the proximal and diaphyseal tibia. After sacrifice, all tibiae were tested in three-point bending.

Results

PTH increased bone volume fraction linearly over time in meta- and epiphysis, accompanied by increased trabecular thickness in both and increased trabecular number only in the latter one. CT-estimated mineralization increased in trabecular and remained constant in cortical bone. Ultimate load and energy were increased and ultimate displacement and stiffness unaltered compared to SHAM rats. For those trabeculae analyzed, bone was formed initially on places where it was most beneficial for increasing their strength and later on to all surfaces.

Mosekilde L, Thomsen JS, McOsker JE (1997) No loss of biomechanical effects after withdrawal of short-term PTH treatment in an aged, osteopenic, ovariectomized rat model. Bone 20:429–437CrossRefPubMed

Sogaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE (1997) A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 20:439–449CrossRefPubMed

Li M, Mosekilde L, Sogaard CH, Thomsen JS, Wronski TJ (1995) Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16:629–635CrossRefPubMed

Mosekilde L, Danielsen CC, Sogaard CH, McOsker JE, Wronski TJ (1995) The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength—assessed in a sexually mature, ovariectomized rat model. Bone 16:223–230CrossRefPubMed

Mosekilde L, Danielsen CC, Sogaard CH, Thorling E (1994) The effect of long-term exercise on vertebral and femoral bone mass, dimensions, and strength—assessed in a rat model. Bone 15:293–301CrossRefPubMed

Baumann BD, Wronski TJ (1995) Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16:247–253CrossRefPubMed

Wronski TJ, Yen C-F (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15:51–58CrossRefPubMed

Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V (1996) Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 11:421–429PubMedCrossRef

Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609–618CrossRefPubMed

10.

Kasukawa Y, Miyakoshi N, Itoi E, Tsuchida T, Tamura Y, Kudo T, Suzuki K, Seki A, Sato K (2004) Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy. J Orthop Res 22:457–464CrossRefPubMed

11.

Zhang KQ, Chen JW, Li QN, Li GF, Tian XY, Huang LF, Bao LH, Wang ML (2002) Effect of intermittent injection of recombinant human parathyroid hormone on bone histomorphometry of ovariectomized rats. Acta Pharmacol Sin 23:659–662PubMed

12.

Lane NE, Yao W, Kinney JH, Modin G, Balooch M, Wronski TJ (2003) Both hPTH(1–34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res 18:2105–2115CrossRefPubMed

13.

Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42:90–97CrossRefPubMed

14.

Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2007) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18:351–362CrossRefPubMed

15.

Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2007) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Bone 41:321–330CrossRefPubMed

16.

Ejersted C, Andreassen TT, Hauge E-M, Melsen F, Oxlund H (1995) Parathyroid hormone (1–34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17:507–511CrossRefPubMed

17.

Gasser JA (1997) Quantitative assessment of bone mass and geometry by pQCT in rats in vivo and site specificity of changes at different skeletal sites. J Jpn Soc Bone Morphometry 7:107–114

18.

Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1–34). Bone 28:237–250CrossRefPubMed

19.

Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1–84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260–273CrossRefPubMed

20.

Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150–159CrossRefPubMed

21.

Sato M, Ma YL, Hock JM, Westmore MS, Vahle J, Villanueva A, Turner CH (2002) Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J Pharmacol Exp Ther 302:304–313CrossRefPubMed

22.

Oxlund H, Dalstra M, Ejersted C, Andreassen TT (2002) Parathyroid hormone induces formation of new cancellous bone with substantial mechanical strength at a site where it had disappeared in old rats. Eur J Endocrinol 146:431–438CrossRefPubMed

23.

Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW (2007) Effects of cyclic vs. daily treatment with human parathyroid hormone (1–34) on murine bone structure and cellular activity. Bone 40:391–398CrossRefPubMed

24.

Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF (1996) Effects of intermittent hPTH (1–34) alone and in combination with1,25(OH)2D3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11:600–611PubMed

25.

Miller MA, Bare SP, Recker RR, Smith SY, Fox J (2008) Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1–84. Bone 42:1175–1183CrossRefPubMed

26.

Guo XE, Kim CH (2002) Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 30:404–411CrossRefPubMed

27.

Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104CrossRefPubMed

28.

Jee WS, Yao W (2001) Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 1:193–207PubMed

29.

Westerlind KC, Wronski TJ, Ritman EL, Luo ZP, An KN, Bell NH, Turner RT (1997) Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc Natl Acad Sci USA 94:4199–4204CrossRefPubMed

30.

Graeff C, Zysset PK, Marin F, Gluer CC (2007) Bone apposition in patients on Teriparatide treatment is preferably directed to skeletal regions of local structural weakness: assessment by high resolution CT based finite element analysis in vivo. J Bone Miner Res 22:S74–S75CrossRef

31.

Li M, Liang H, Shen Y, Wronski TJ (1999) Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 24:95–100CrossRefPubMed

32.

Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156CrossRefPubMed

33.

Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer K (2005) Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 37:87–95CrossRefPubMed

34.

Mulder L, Koolstra JH, Van Eijden TM (2004) Accuracy of microCT in the quantitative determination of the degree and distribution of mineralization in developing bone. Acta Radiol 45:769–777CrossRefPubMed

35.

Verhulp E, van Rietbergen B, Huiskes R (2004) A three-dimensional digital image correlation technique for strain measurements in microstructures. J Biomech 37:1313–1320CrossRefPubMed

36.

Brouwers JEM, van Rietbergen B, Huiskes R (2007) No effects of in vivo micro-CT radiation on structural parameters and bone marrow cells in proximal tibia of wistar rats detected after eight weekly scans. J Orthop Res 25:1325–1332CrossRefPubMed

37.

Sato M, Vahle J, Schmidt A, Westmore M, Smith S, Rowley E, Ma LY (2002) Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143:3230–3242CrossRefPubMed

38.

Sato M, Zeng GQ, Turner CH (1997) Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138:4330–4337CrossRefPubMed

39.

Washimi Y, Ito M, Morishima Y, Taguma K, Ojima Y, Uzawa T, Hori M (2007) Effect of combined humanPTH(1–34) and calcitonin treatment in ovariectomized rats. Bone 41:786–793CrossRefPubMed

40.

Shen V, Birchman R, Wu DD, Lindsay R (2000) Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion. J Bone Miner Res 15:740–746CrossRefPubMed

41.

Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447–1452CrossRefPubMed

42.

Burr DB (2005) Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 3:19–24CrossRefPubMed

43.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149–157CrossRefPubMed

44.

Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ (2007) Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int 18:973–979CrossRefPubMed

45.

Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, Lindsay R (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513–520CrossRefPubMed

46.

Gasser JA (1995) Assessing bone quantity by pQCT. Bone 17:S145–S154

47.

Bourrin S, Ammann P, Bonjour JP, Rizzoli R (2002) Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 30:195–200CrossRefPubMed

48.

Shen V, Birchman R, Liang XG, Wu DD, Lindsay R, Dempster DW (1997) Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats. Bone 21:345–351CrossRefPubMed

49.

Kobayashi M, Hara K, Akiyama Y (2002) Effects of vitamin K2 (menatetrenone) on calcium balance in ovariectomized rats. Jpn J Pharmacol 88:55–61CrossRefPubMed

50.

Hara K, Kobayashi M, Akiyama Y (2007) Influence of bone osteocalcin levels on bone loss induced by ovariectomy in rats. J Bone Miner Metab 25:345–353CrossRefPubMed

51.

Kippo K, Hannuniemi R, Isaksson P, Lauren L, Osterman T, Peng Z, Tuukkanen J, Kuurtamo P, Vaananen HK, Sellman R (1998) Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J Bone Miner Res 13:287–296CrossRefPubMed

52.

Mosekilde L, Tornvig L, Thomsen JS, Orhii PB, Banu MJ, Kalu DN (2000) Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia. Bone 26:643–651CrossRefPubMed

53.

Waarsing JH, Day JS, Verhaar JAN, Ederveen AGH, Weinans H (2006) Bone loss dynamics result in trabecular alignment in aging and ovariectomized rats. J Orthop Res 24:926–935CrossRefPubMed

54.

Slovik DM, Neer RM, Potts JTJ (1981) Short-term effects of synthetic human parathyroid hormone-(1–34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 68:1261–1271CrossRefPubMed

55.

Hodsman AB, Steer BM, Fraher LJ, Drost DJ (1991) Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1–38) and salmon calcitonin in osteoporotic patients. Bone Miner 14:67–83CrossRefPubMed

56.

Reeve J, Davies UM, Hesp R, McNally E, Katz D (1990) Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. Br Med J 301:314–318CrossRef

57.

Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Chi JD, Taves DH, Drost D (1997) A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620–628CrossRefPubMed

58.

Fajardo R, Cory E, Patel N, Nazarian A, Snyder B, Bouxsein ML (2007) Specimen size and porosity can introduce error into micro-CT-based tissue mineral density measurements. Bone 44:76–84

59.

Cory E, Patel N, Nazarian A, Snyder B, Bouxsein ML, Fajardo R (2007) Effect of surrounding tissue on density evaluation via microcomputed tomography. Trans Orthop Res Soc 32:373

Title: Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT
Authors: J. E. M. Brouwers
B. van Rietbergen
R. Huiskes
K. Ito
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0882-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT

Abstract

Summary

Introduction

Methods

Results

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Please log in to get access to this content

Other articles of this Issue 11/2009

Global vitamin D status and determinants of hypovitaminosis D

Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D

“Pathologic” fractures: should these be included in epidemiologic studies of osteoporotic fractures?

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

Factors influencing the treatment of osteoporosis following fragility fracture

Radiographic trabecular 2D and 3D parameters of proximal femoral bone cores correlate with each other and with yield stress